Manage New Warnings About Clarithromycin and Cardiovascular Risk

April 2018

You may see drug-disease alerts pop up about an increased risk of CV events or death with clarithromycin...due to a new FDA warning.

The focus is on patients with coronary artery disease (CAD).

Macrolide antibiotics...clarithromycin, erythromycin, and azithromycin...already have warnings about QT prolongation and torsades.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote